Novel Adsorbent For Industrial Wastewater Treatment Applications

In this study, the hydroxyapatite powder is investigated for both of methylene blue and thymol blue in aqueous solution. The physical and chemical properties of the adsorbent were evaluated systematically using the different techniques including Microsoft Excel programming, linear regression model and also the coefficient of determination. Batch adsorption experiments were conducted to determine the effect of contact time, solution pH, initial dye concentrations, and also the adsorbent dosage on adsorption. The adsorption kinetic parameters confirmed the better fitting of pseudo-second order kinetic model for both of methylene blue and thymol blue. The isotherm data of methylene blue and thymol blue could be well described by the Freundlich isotherm model which means the adsorption is multilayer adsorption with non-uniform distribution of adsorption heat and affinities over the heterogeneous surface. The maximum adsorption capacity (KF) of methylene blue and thymol blue is found to be 0.2736 (L/mg) and 11.18407 (L/mg) respectively. The high specific surface area and the porous structure with some acidic functional groups on the surface were obviously responsible for high dyes adsorption onto hydroxyapatite (HA). Adsorption kinetics data were modeled with the application of Pseudo first order, Pseudo second order and Intraparticle diffusion models. The results revealed that the Pseudo second order model was the best fitting model. Which means that, the adsorption mechanism followed two stages in which the first one was fast and the other was slower step. Which means the adsorption of dye molecules was limited by intra particle diffusion and film diffusion, as well as the adsorption rate in both of adsorption system are depends only on the slower step. The Boyd plot exposed that the intra-particle diffusion was the rate controlling step of the adsorption process of both of methylene blue and thymol blue molecules by HA powder. However, the adsorption of methylene blue molecules (basic solution) using of HA as adsorbent particles is found to be extremely preferable than thymol blue molecules

Development of novel adsorbent for industrial wastewater treatment

The main objective of this research project is to perform some experimental procedures to inform the ability of the novel adsorbent used in this project. The chemical modification of the adsorbent is the chemical oxidation of pure powder chitosan using some specific redox pairs which are potassium dichromate and sodium bisulphite. After preparing the modified chitosan, there are some parameters that must be discussed during the adsorption process. The first parameter is the time parameter, showing experimentally the optimum time for adsorption under certain conditions by collecting values of absorbance and concentration of thymol blue adsorbed after the process from the spectrophotometer showing that the optimum time is 120 minutes. While for the optimum pH experiment, it is shown that optimum pH is 4, 0.5% v/v is optimum concentration, and 0.05 grams is the optimum dose for the adsorbent. Then after computing these conditions and values of absorbance, some calculations and classifications are done to show the reaction kinetics and isotherm classification of the process. By performing some equations using mathematical rules it is provided that the reaction is not a first order reaction, showing by calculations and graphs that the reaction is a second order reaction. Also, to know the classification of the process other mathematical relations are done calculating slope and R2 to show whether the process reaction is a Langumir or Frendulish, showing that the reaction process is a Frendulish process having a greater value of R2

Impact of opioid-free analgesia on pain severity and patient satisfaction after discharge from surgery: multispecialty, prospective cohort study in 25 countries

Background: Balancing opioid stewardship and the need for adequate analgesia following discharge after surgery is challenging. This study aimed to compare the outcomes for patients discharged with opioid versus opioid-free analgesia after common surgical procedures.Methods: This international, multicentre, prospective cohort study collected data from patients undergoing common acute and elective general surgical, urological, gynaecological, and orthopaedic procedures. The primary outcomes were patient-reported time in severe pain measured on a numerical analogue scale from 0 to 100% and patient-reported satisfaction with pain relief during the first week following discharge. Data were collected by in-hospital chart review and patient telephone interview 1 week after discharge.Results: The study recruited 4273 patients from 144 centres in 25 countries; 1311 patients (30.7%) were prescribed opioid analgesia at discharge. Patients reported being in severe pain for 10 (i.q.r. 1-30)% of the first week after discharge and rated satisfaction with analgesia as 90 (i.q.r. 80-100) of 100. After adjustment for confounders, opioid analgesia on discharge was independently associated with increased pain severity (risk ratio 1.52, 95% c.i. 1.31 to 1.76; P < 0.001) and re-presentation to healthcare providers owing to side-effects of medication (OR 2.38, 95% c.i. 1.36 to 4.17; P = 0.004), but not with satisfaction with analgesia (beta coefficient 0.92, 95% c.i. -1.52 to 3.36; P = 0.468) compared with opioid-free analgesia. Although opioid prescribing varied greatly between high-income and low- and middle-income countries, patient-reported outcomes did not.Conclusion: Opioid analgesia prescription on surgical discharge is associated with a higher risk of re-presentation owing to side-effects of medication and increased patient-reported pain, but not with changes in patient-reported satisfaction. Opioid-free discharge analgesia should be adopted routinely

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century